I. RESTATEMENT (Details 1) - USD ($)	3 Months Ended				6 Months Ended
	Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2019	Dec. 31, 2018	Mar. 31, 2020	Mar. 31, 2019
Research and development	$ 4,458,547		$ 2,832,546		$ 8,711,360	$ 6,304,260
Total operating expenses	7,017,069		4,457,369		13,908,778	9,618,245
Operating loss	(6,718,343)		(4,306,600)		(13,574,546)	(9,341,062)
Net loss	(9,067,818)	$ (5,531,360)	(6,447,681)	$ 1,245,902	(14,599,178)	(5,201,779)
Net loss available to common shareholders	$ (9,089,552)		$ (6,447,681)		$ (14,620,912)	$ (5,201,779)
Net loss per share - basic and diluted	$ (.25)				$ (0.41)
Previously Reported
Research and development	$ 4,402,347				$ 8,598,960
Total operating expenses	6,960,869				13,796,378
Operating loss	(6,662,143)				(13,462,146)
Net loss	(9,011,618)				(14,486,778)
Net loss available to common shareholders	$ (9,033,352)				$ (14,508,512)
Net loss per share - basic and diluted	$ (.25)				$ (0.41)
Adjustment
Research and development	$ 56,200				$ 112,400
Total operating expenses	56,200				112,400
Operating loss	(56,200)				(112,400)
Net loss	(56,200)				(112,400)
Net loss available to common shareholders	$ (56,200)				$ (112,400)
Net loss per share - basic and diluted